Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Home
/
update
/
details

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

NextEdge Admin

10 Jan 2025

1 min 37 sec

BRCA-Mutated,Breast Cancer,HER2-negative

NICE has approved Lynparza (olaparib) for NHS use in England and Wales for adults with HER2-negative, locally advanced or metastatic breast cancer who have germline BRCA1 or BRCA2 mutations, following chemotherapy.

Germline BRCA1/2 mutations account for 5–10% of breast cancers, making genetic testing essential for optimal treatment. The OlympiAD phase 3 trial demonstrated that olaparib significantly delays disease progression or death compared to standard chemotherapy, reducing the risk by 42%. Its safety profile remains consistent with known effects.

Olaparib, a precision PARP inhibitor, disrupts cancer cells’ DNA-repair mechanisms, leading to tumour cell death. Professor Andrew Tutt highlighted its impact in improving outcomes for patients with inherited BRCA mutations. AstraZeneca UK President Tom Keith-Roach welcomed NICE’s recommendation, marking the company’s 26th cancer medicine approval by NICE and SMC since 2021.

BRCA mutation testing is available and reimbursed via the NHS National Genomic Test Directory. NICE’s decision underscores the role of genetic testing in ensuring targeted therapies reach eligible patients, advancing precision medicine in oncology.